Overview

• Cancer diagnostics firm's preliminary Q4 revenue rises 11%, slightly beating analyst expectations

• Company anticipates full-year 2025 revenue growth of 10%

• Company announces CFO transition, Abhishek Jain to succeed Jeff Sherman

Outlook

• NeoGenomics anticipates preliminary Q4 2025 revenue of approximately $190 mln

• Company expects prelim full-year 2025 revenue of approximately $727 mln

• NeoGenomics aims to continue double-digit revenue growth trajectory

Result Drivers

• CANCER TESTING PARTNER - NeoGenomics attributes revenue growth to its role as a preferred partner for cancer testing in community settings, offering a broad oncology test menu

• BROAD TEST MENU - Co highlights its extensive oncology test offerings, including innovations in therapy selection and recurrence monitoring, as key to revenue growth

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Neogenomics Inc is $14.00, about 6.4% above its January 9 closing price of $13.16

• The stock recently traded at 81 times the next 12-month earnings vs. a P/E of 49 three months ago

Press Release: ID:nBwy9YB3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)